Topics in pediatric leukemia - Myelodysplastic and myeloproliferative disorders of childhood

MedGenMed Medscape General Medicine

Volumn 7, Issue 1, 2005, Pages

  Lasky, Joseph ^a   Sakamoto, Kathleen M ^a  

^a MATTEL CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ANGIOGENESIS INHIBITOR; ARSENIC TRIOXIDE; COMPLEMENTARY RNA; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOKINE RECEPTOR ANTAGONIST; DIPHTHERIA TOXIN; ENZYME INHIBITOR; ETOPOSIDE; FLUDARABINE; GLUTATHIONE TRANSFERASE INHIBITOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; IMMUNOMODULATING AGENT; INFLIXIMAB; ISOTRETINOIN; PROTEASOME INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TIPIFARNIB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SUSCEPTIBILITY; CHILD; CHILDHOOD CANCER; CLINICAL FEATURE; DISEASE CLASSIFICATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; RISK FACTOR; SURVIVAL RATE;

EID: 25144488611     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Emanuel PD. Myelodysplasia and myeloproliferative disorders in childhood: an update. Br J Haematol. 1999;105:852-863.
2. Philip A, Pizzo DGP. Principles and Practice of Pediatric Oncology. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2002.
3. Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002;32:148-152.
4. Chan GC, Wang WC, Raimondi SC, et al. Myelodysplastic syndrome in children: differentiation from acute myeloid leukemia with a low blast count. Leukemia. 1997;11:206-211.
5. Harada H, Harada Y, Niimi H, Kyo T, Kimura A, Inaba T. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood. 2004;103:2316-2324.
6. Pedersen-Bjergaard J, Christiansen DH, Andersen MK, Skovby F, et al. Causality of myelodysplasia and acute myeloid leukemia and their genetic abnormalities. Leukemia. 2002;16:2177-2184.
7. Hasle H, Niemeyer CM, Chessells JM, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia. 2003;17:277-282.
8. Mandel K, Dror Y, Poon A, Freedman MH. A practical, comprehensive classification for pediatric myelodysplastic syndromes: the CCC system. J Pediatr Hematol Oncol. 2002;24:596-605.
9. Narendran A, Hawkins LM, Ganjavi H, et al. Characterization of bone marrow stromal abnormalities in a patient with constitutional trisomy 8 mosaicism and myelodysplastic syndrome. Pediatr Hematol Oncol. 2004;21:209-221.
10. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189-199.
11. Knapp RH, Dewald GW, Pierre RV. Cytogenetic studies in 174 consecutive patients with preleukemic or myelodysplastic syndromes. Mayo Clin Proc. 1985;60:507-516.
12. Flotho C, Valcamonica S, Mach-Pascual S, et al. RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia. 1999;13:32-37.
13. Side LE, Emanuel PD, Taylor B, et al. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood. 1998;92:267-272.
14. Gurbuxani S, Vyas P, Crispino JD. Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood. 2004;103:399-406.
15. Ahmed M, Sternberg A, Hall G, et al. Natural history of GATA1 mutations in Down syndrome. Blood. 2004;103:2480-2489.
16. Lange BJ, Kobrinsky N, Barnard DR, et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891.Blood. 1998;91:608-615.
17. Luna-Fineman S, Shannon KM, Atwater SK, et al. Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients. Blood. 1999;93:459-466.
18. Mantadakis E, Shannon KM, Singer DA, et al. Transient monosomy 7: a case series in children and review of the literature. Cancer. 1999;85:2655-2661.
19. Locatelli F, Niemeyer C, Angelucci E, et al. Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: a report from the European Working Group on Myelodysplastic Syndrome in Childhood. J Clin Oncol. 1997;15:566-573.
20. Barnard DR, Lange B, Alonzo TA, et al. Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation. Blood. 2002;100:427-434.
21. Kardos G, Baumann I, Passmore SJ, et al. Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7. Blood. 2003;102:1997-2003.
22. Sierra J, Perez WS, Rozman C, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood. 2002;100:1997-2004.
23. Valera ET, Latorre Mdo R, Mendes WL, et al. Treatment of pediatric myelodysplastic syndromes and juvenile myelomonocytic leukemia: the Brazilian experience in the past decade. Leuk Res. 2004;28:933-939.
24. Virchis A, Koh M, Rankin P, et al. Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes. Br J Haematol. 2004;124:26-32.
25. Woods WG, Neudorf S, Gold S, et al; Children's Cancer Group. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from the Children's Cancer Group. Blood. 2001;97:56-62.
26. Yusuf U, Frangoul HA, Gooley TA, et al. Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience. Bone Marrow Transplant. 2004;33:805-814.
27. Faderl S, Kantarjian HM. Novel therapies for myelodysplastic syndromes. Cancer. 2004;101:226-241.
28. Borojevic R, Roela RA, Rodarte RS, et al. Bone marrow stroma in childhood myelodysplastic syndrome: composition, ability to sustain hematopoiesis in vitro, and altered gene expression. Leuk Res. 2004;28:831-844.
29. Kurzrock R, Albitar M, Cortes JE, et al. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol. 2004;22:1287-1292.
30. Kurzrock R, Kantarjian HM, Cortes JE, et al. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood. 2003;102:4527-4534.
31. Raza A, Meyer P, Dutt D, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood. 2001;98:958-965.
32. List AF, Glinsmann-Gibson B. Efficacy and safety of CC5013 for treatment of anemia in patients with myelodysplastic syndromes (MDS). Blood. 2003;102:184a.
33. Roboz GJ, Giles F. Phase I trial of PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2003;102:361a.
34. Stasi R, Amadori S. Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes. Br J Haematol. 2002;116:334-337.
35. List AF, Mason SG. Trisenox (arsenic trioxide) in patients with myelodysplastic syndromes (MDS): preliminary findings in a phase 2 clinical study. Blood. 2003;102:423a.
36. Smith FO, King R, Nelson G, et al; National Marrow Donor Program. Unrelated donor bone marrow transplantation for children with juvenile myelomonocytic leukaemia. Br J Haematol. 2002;116:716-724.
37. Arceci RJ, Longley BJ, Emanuel PD. Atypical cellular disorders. Hematology (Am Soc Hematol Educ Program). 2002:297-314.
38. Lutz P, Zix-Kieffer I, Souillet G, et al. Juvenile myelomonocytic leukemia: analysis of treatment results in the EORTC Children's Leukemia Cooperative Group (CLCG). Bone Marrow Transplant. 1996;18:1111-1116.